BD Diagnostics has announced the FDA clearance and launch of the BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay for the direct qualitative detection of T. vaginalis DNA in endocervical and vaginal samples as well as neat urine specimens to aid in the diagnosis of trichomoniasis on the BD Viper System with XTR Technology.
Genital inflammation caused by trichomoniasis can increase a woman’s susceptibility to HIV infection. In HIV-infected women, trichomoniasis may increase the likelihood of HIV transmission to sex partners. Furthermore, trichomoniasis is often asymptomatic. For these reasons, screening for T. vaginalis is recommended in women considered to be at high risk for infection.
“The global prevalence of trichomoniasis is on the rise and there are more asymptomatic cases than previously thought,” says Chris Demiris, Worldwide Group Marketing Manager, BD Diagnostics–Diagnostic Systems, Women’s Health and Cancer. “The availability of an automated platform is especially important as clinical and public health communities embrace the need for a test that provides timely and accurate diagnosis of trichomoniasis when screening high-risk populations.”
The BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay features automated DNA extraction and simultaneous amplification and detection. It allows laboratories to test samples in panel mode for T. vaginalis, C. trachomatis, and N. gonorrhea or in batch mode for chlamydia and gonorrhea, trichomonas, and herpes on the same automated platform. Learn more about the BD Viper System.
